BOSTON, Jan 12, 2009 (BUSINESS WIRE) --
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
that it will participate in the 27th Annual JP Morgan Healthcare
Conference in San Francisco, CA.
CEO Alan Milinazzo is scheduled to give a presentation on Wednesday,
January 14th, at 5:30 PM Eastern Time at The Westin St. Francis. During
Mr. Milinazzo's presentation he will reiterate the Company's previously
announced fourth quarter 2008 revenue guidance of $130-135 million.
Mr. Milinazzo stated, "We are especially pleased to reiterate our fourth
quarter revenue guidance despite approximately $3-$4 million of negative
foreign currency impact. Additionally, though Blackstone's fourth
quarter 2008 revenue was lower than the prior year, it increased
sequentially from the third quarter. For the full year 2009 we are
forecasting a year-over-year increase in Blackstone revenue of
approximately 8%-12%. This increase reflects the estimated impact of a
number of planned new product introductions including our new Firebird(TM)
pedicle screw system and Trinity(R) Evolution, a stem cell-based allograft
developed in collaboration with the Musculoskeletal Transplant
Foundation."
A live audio webcast of the presentation will be available on the
company's website at www.orthofix.com.
About Orthofix International, N.V.
Orthofix International N.V., a global medical device company, offers a
broad line of minimally invasive surgical, as well as non-surgical,
products for the spine, orthopedic, and sports medicine market sectors
that address the lifelong bone-and-joint health needs of patients of all
ages, helping them achieve a more active and mobile lifestyle.
Orthofix's products are widely distributed around the world to
orthopedic surgeons, hospitals and patients via Orthofix's sales
representatives and its subsidiaries, including Breg, Inc. and
Blackstone Medical, Inc. In addition, Orthofix is collaborating in R&D
partnerships with leading institutions such as the Musculoskeletal
Transplant Foundation, the Orthopedic Research and Education Foundation,
the Cleveland Clinic Foundation, and the National Osteoporosis
Institute. For more information about Orthofix, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of Orthofix and its subsidiaries and are based on
management's current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ
materially from those contemplated by the forward-looking statements.
Factors that could cause or contribute to such differences may include,
but are not limited to, risks relating to the expected sales of its
products, including recently launched products, unanticipated
expenditures, changing relationships with customers, suppliers and
strategic partners, risks relating to the protection of intellectual
property, changes to the reimbursement policies of third parties,
changes to and interpretation of governmental regulation of medical
devices, the impact of competitive products, changes to the competitive
environment, the acceptance of new products in the market, conditions of
the orthopedic industry and the economy, corporate development and
market development activities, including acquisitions or divestitures,
unexpected costs or operating unit performance related to recent
acquisitions and other factors described in our annual report on Form
10-K and other periodic reports filed by the Company with the Securities
and Exchange Commission.
Important Additional Information
Ramius Capital and certain of its affiliates have filed a definitive
proxy statement with the SEC to solicit written requests from
shareholders of Orthofix to call a special general meeting of
shareholders for the purpose of making changes to the composition of
Orthofix's board of directors. Orthofix has filed with the SEC a
preliminary proxy statement in connection with its intent to solicit
written requests from shareholders in opposition to Ramius'
solicitation. If Orthofix holds a special general meeting at Ramius' and
other shareholders' request, Orthofix intends to file with the SEC, and
distribute to shareholders, a proxy statement opposing proposals made by
Ramius. SHAREHOLDERS ARE URGED TO READ ORTHOFIX'S DEFINITIVE PROXY
MATERIALS AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED WITH THE
SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Investors and shareholders may obtain (when they are
available) a free copy of proxy statements filed with the SEC by
Orthofix at the SEC's website at www.sec.gov
or by contacting Georgeson, 199 Water Street, 26th Floor, New
York, NY 10038 or by calling (212) 440-9800 (bankers and brokers) or
toll-free (800) 323-4133 (all others).
Orthofix International N.V. and its directors and certain executive
officers are participants in the solicitation of consent revocations
from shareholders of Orthofix, as well as the solicitation of proxies in
connection with a special general meeting of shareholders, if such a
meeting is called. The names of such persons are: James F. Gero, Peter
J. Hewett, Jerry C. Benjamin, Charles W. Federico, Dr. Guy J. Jordan,
Ph.D., Thomas J. Kester, CPA, Alan W. Milinazzo, Maria Sainz, Dr. Walter
P. von Wartburg, Kenneth R. Weisshaar, Robert S. Vaters, Michael
Simpson, Bradley R. Mason, Raymond C. Kolls, J.D. and Michael M.
Finegan. Information regarding such participants, as well as each such
person's respective interests in Orthofix by security holdings or
otherwise, is set forth in Orthofix's proxy statement relating to the
2008 annual general meeting of shareholders, which may be obtained free
of charge at the SEC's website at www.sec.gov
and Orthofix's website at www.orthofix.com.
More current information regarding such persons, as well as each such
person's respective interests in Orthofix by security holdings or
otherwise, will be set forth in the definitive proxy statement materials
to be filed with the SEC and distributed to shareholders by Orthofix as
described above.
SOURCE: Orthofix International N.V.
Orthofix International N.V.
Dan Yarbrough, 617-912-2903
Vice President of Investor Relations
danyarbrough@orthofix.com
Copyright Business Wire 2009
News Provided by COMTEX